Objective： To assess the effect and adverse reaction of total glucosides of paeony capsule （TGPC） in combining with citirizine for the treatment of chronic urticaria. Methods： A total of 120 patients were assigned...Objective： To assess the effect and adverse reaction of total glucosides of paeony capsule （TGPC） in combining with citirizine for the treatment of chronic urticaria. Methods： A total of 120 patients were assigned to two groups by lottery, 65 in the treated group and 55 in the control group. They all were orally treated with citirizine tablet 10 mg per day, but to the treated group, additional 0.2 g TGPC was given three times per day, the therapeutic course for both groups was 4 weeks. The effectiveness of treatment was observed, and the changes of total symptom score, serum levels of interleukin-4 （IL-4）, and immunoglobulin E （IgE） were measured before and after treatment. Moreover, a follow- up was carded out one month after ending the treatment. Results： The dropped cases were two in the treated group and seven in the control group; so, the study was accomplished on 63 patients in the treated group and 48 patients in the control group. The total effective rate was assessed at 73.02% （46/63） in the treated group, which was significantly higher than 47.92% （23/48） in the control group （P〈0.01）. After treatment, the total symptom score decreased in both groups, but the decrement in the treated group was more significant （P〈0.05）. Serum levels of IL-4 and IgE in the treated group lowered significantly, while the changes in the control group were insignificant, so statistical significant differences were shown between groups （P〈0.01）. A follow-up study showed that the relapse rate in the treated group was 30.00% （6/20）, while that in the control group was 90.00% （9/10）, and the former was lower than the latter （P〈0.01）. Adverse reactions, revealed as drowsiness, dizziness, and weakness, were seen in eight cases and seven cases in the two groups, respectively. Besides, mild diarrhea occurred in two cases of the treated group. Conclusions： The treatment of TGPC combining citirizine shows definite curative effect in treating chronic urticaria, with low relaps展开更多
Objective： To observe the efficacy and safety of total glucosides of paeony capsule （TGPC） in patients with mild and moderate alopecia areata. Methods： A total of 86 outpatients were randomly allocated into two gr...Objective： To observe the efficacy and safety of total glucosides of paeony capsule （TGPC） in patients with mild and moderate alopecia areata. Methods： A total of 86 outpatients were randomly allocated into two groups of TGPC （treatment, 44 cases） and compound glycyrrhizin tablet （control, 42 cases）. The treatment group was given oral TGPC, three times daily and 600 mg per time; the control group was given oral compound glycyrrhizin tablets, three times daily and 50 mg per time. In addition, both groups were given 10 mg of vitamin B2 and tapped the bold patches with massage. The treatment course was three months for both groups. Peripheral blood T-cell subsets （CD3^＋CD4^＋, CD3^＋CD8^＋, Th, Ts, Th/Ts） of 10 patients randomly selected from each group respectively were tested before and after three months of treatment. The effectiveness and adverse reaction of all cases were observed each month. The safety was evaluated according to the incidence rate of adverse reaction. Results： In the treatment group, the cured and markedly effective rate was 36.36% （16/44）, 50.00% （22/44） and 68.18% （30/44） at the end of first, second and third month of treatment, respectively, and the incidence rate of adverse reaction was 13.64% （6/44）. In the control group, the cured and markedly effective rate was 38.10% （16/42）, 57.14% （24/42） and 71.43% （30/42）, respectively, and the incidence rate of adverse reaction was 16.67% （7/42）. The cured and markedly effective rate and the incidence rate of adverse reaction were similar in both groups （P〉0.05）. TGPC and compound glycyrrhizin tablet can inhibit CD3^＋CD4^＋ and CD3^＋CD8^＋, and decrease the ratio of Th/Ts （P〈0.05）. Conclusion： TGPC is effective and safe in the treatment of alopecia areata.展开更多
目的:系统评价白芍总苷胶囊联合柳氮磺吡啶片对比柳氮磺吡啶片治疗强直性脊柱炎的疗效和安全性,为其临床应用提供循证参考。方法:计算机检索Pub Med、EMBase、Medline、Cochrane图书馆、中国期刊全文数据库、中文科技期刊数据库、万方...目的:系统评价白芍总苷胶囊联合柳氮磺吡啶片对比柳氮磺吡啶片治疗强直性脊柱炎的疗效和安全性,为其临床应用提供循证参考。方法:计算机检索Pub Med、EMBase、Medline、Cochrane图书馆、中国期刊全文数据库、中文科技期刊数据库、万方数据库中相关文献,收集白芍总苷胶囊联合柳氮磺吡啶片(试验组)对比单用柳氮磺吡啶片(对照组)治疗强直性脊柱炎疗效(总有效率、晨僵时间、扩胸度、关节疼痛指数、红细胞沉降率、C反应蛋白水平、Schober试验值)和安全性(腹泻、白细胞减少、肝功异常发生率)的随机对照试验(RCT),对符合纳入标准的文献进行资料提取,并采用Cochrane风险偏倚评估工具5.1.0进行质量评价后,采用Rev Man 5.3统计软件进行Meta分析。结果:共纳入9项RCT,合计593例患者。Meta分析结果显示,试验组患者总有效率[OR=3.90,95%CI(2.24,6.80),P<0.01]、晨僵时间[MD=-5.05,95%CI(-6.96,-3.14),P<0.01]、扩胸度[MD=0.26,95%CI(0.07,0.46),P<0.01]、关节疼痛指数[MD=-1.28,95%CI(-2.13,-0.43),P<0.01]、C反应蛋白水平[MD=-0.78,95%CI(-1.44,-0.12),P=0.02]、肝功能异常发生率[MD=0.23,95%CI(0.10,0.50),P<0.01]等方面均优于对照组,而两组患者红细胞沉降率[MD=-2.68,95%CI(-8.45,3.08),P=0.36]、Schober试验值[MD=0.24,95%CI(-0.15,0.63),P=0.23]、腹泻发生率[OR=1.39,95%CI(0.62,3.12),P=0.43]、白细胞减少发生率[OR=0.33,95%CI(0.06,1.79),P=0.20]比较,差异均无统计学意义。结论:白芍总苷胶囊联合柳氮磺吡啶片可显著提高治疗强直性脊柱炎的总有效率,缩短晨僵时间,扩大扩胸度,降低关节疼痛指数和C反应蛋白水平,同时能降低肝功能异常的发生。展开更多
文摘Objective： To assess the effect and adverse reaction of total glucosides of paeony capsule （TGPC） in combining with citirizine for the treatment of chronic urticaria. Methods： A total of 120 patients were assigned to two groups by lottery, 65 in the treated group and 55 in the control group. They all were orally treated with citirizine tablet 10 mg per day, but to the treated group, additional 0.2 g TGPC was given three times per day, the therapeutic course for both groups was 4 weeks. The effectiveness of treatment was observed, and the changes of total symptom score, serum levels of interleukin-4 （IL-4）, and immunoglobulin E （IgE） were measured before and after treatment. Moreover, a follow- up was carded out one month after ending the treatment. Results： The dropped cases were two in the treated group and seven in the control group; so, the study was accomplished on 63 patients in the treated group and 48 patients in the control group. The total effective rate was assessed at 73.02% （46/63） in the treated group, which was significantly higher than 47.92% （23/48） in the control group （P〈0.01）. After treatment, the total symptom score decreased in both groups, but the decrement in the treated group was more significant （P〈0.05）. Serum levels of IL-4 and IgE in the treated group lowered significantly, while the changes in the control group were insignificant, so statistical significant differences were shown between groups （P〈0.01）. A follow-up study showed that the relapse rate in the treated group was 30.00% （6/20）, while that in the control group was 90.00% （9/10）, and the former was lower than the latter （P〈0.01）. Adverse reactions, revealed as drowsiness, dizziness, and weakness, were seen in eight cases and seven cases in the two groups, respectively. Besides, mild diarrhea occurred in two cases of the treated group. Conclusions： The treatment of TGPC combining citirizine shows definite curative effect in treating chronic urticaria, with low relaps
文摘Objective： To observe the efficacy and safety of total glucosides of paeony capsule （TGPC） in patients with mild and moderate alopecia areata. Methods： A total of 86 outpatients were randomly allocated into two groups of TGPC （treatment, 44 cases） and compound glycyrrhizin tablet （control, 42 cases）. The treatment group was given oral TGPC, three times daily and 600 mg per time; the control group was given oral compound glycyrrhizin tablets, three times daily and 50 mg per time. In addition, both groups were given 10 mg of vitamin B2 and tapped the bold patches with massage. The treatment course was three months for both groups. Peripheral blood T-cell subsets （CD3^＋CD4^＋, CD3^＋CD8^＋, Th, Ts, Th/Ts） of 10 patients randomly selected from each group respectively were tested before and after three months of treatment. The effectiveness and adverse reaction of all cases were observed each month. The safety was evaluated according to the incidence rate of adverse reaction. Results： In the treatment group, the cured and markedly effective rate was 36.36% （16/44）, 50.00% （22/44） and 68.18% （30/44） at the end of first, second and third month of treatment, respectively, and the incidence rate of adverse reaction was 13.64% （6/44）. In the control group, the cured and markedly effective rate was 38.10% （16/42）, 57.14% （24/42） and 71.43% （30/42）, respectively, and the incidence rate of adverse reaction was 16.67% （7/42）. The cured and markedly effective rate and the incidence rate of adverse reaction were similar in both groups （P〉0.05）. TGPC and compound glycyrrhizin tablet can inhibit CD3^＋CD4^＋ and CD3^＋CD8^＋, and decrease the ratio of Th/Ts （P〈0.05）. Conclusion： TGPC is effective and safe in the treatment of alopecia areata.
文摘目的:系统评价白芍总苷胶囊联合柳氮磺吡啶片对比柳氮磺吡啶片治疗强直性脊柱炎的疗效和安全性,为其临床应用提供循证参考。方法:计算机检索Pub Med、EMBase、Medline、Cochrane图书馆、中国期刊全文数据库、中文科技期刊数据库、万方数据库中相关文献,收集白芍总苷胶囊联合柳氮磺吡啶片(试验组)对比单用柳氮磺吡啶片(对照组)治疗强直性脊柱炎疗效(总有效率、晨僵时间、扩胸度、关节疼痛指数、红细胞沉降率、C反应蛋白水平、Schober试验值)和安全性(腹泻、白细胞减少、肝功异常发生率)的随机对照试验(RCT),对符合纳入标准的文献进行资料提取,并采用Cochrane风险偏倚评估工具5.1.0进行质量评价后,采用Rev Man 5.3统计软件进行Meta分析。结果:共纳入9项RCT,合计593例患者。Meta分析结果显示,试验组患者总有效率[OR=3.90,95%CI(2.24,6.80),P<0.01]、晨僵时间[MD=-5.05,95%CI(-6.96,-3.14),P<0.01]、扩胸度[MD=0.26,95%CI(0.07,0.46),P<0.01]、关节疼痛指数[MD=-1.28,95%CI(-2.13,-0.43),P<0.01]、C反应蛋白水平[MD=-0.78,95%CI(-1.44,-0.12),P=0.02]、肝功能异常发生率[MD=0.23,95%CI(0.10,0.50),P<0.01]等方面均优于对照组,而两组患者红细胞沉降率[MD=-2.68,95%CI(-8.45,3.08),P=0.36]、Schober试验值[MD=0.24,95%CI(-0.15,0.63),P=0.23]、腹泻发生率[OR=1.39,95%CI(0.62,3.12),P=0.43]、白细胞减少发生率[OR=0.33,95%CI(0.06,1.79),P=0.20]比较,差异均无统计学意义。结论:白芍总苷胶囊联合柳氮磺吡啶片可显著提高治疗强直性脊柱炎的总有效率,缩短晨僵时间,扩大扩胸度,降低关节疼痛指数和C反应蛋白水平,同时能降低肝功能异常的发生。
